Opdualag (nivolumab and relatlimab)

pCPA File Number: 22581

Negotiation Status:

Concluded with an LOI

Indication(s):

Unresectable or metastatic melanoma in adult and pediatric patients 12 years of age or older who have not received prior systemic therapy for unresectable or metastatic melanoma

Sponsor/Manufacturer:

Bristol Myers Squibb Canada Inc.

CDA-AMC Project Number:

PC0329-000

pCPA Engagement Letter Issued:

2024-06-21

Negotiation Process Concluded:

2024-08-08